Skip to main content

Table 1 Characteristics of the 12 patients

From: A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors

No.

Sex

Age

Primary cancer

TNM

Stage

Metastasis

Total %IDa

%ID/kgb

1

F

48

Breast

T2N2M2

IV

Bone

0.025

3.00

2

M

48

Esophagus

T1N0M1

IV

Pelvis

0.001

1.41

Rectum

0.003

1.03

3

M

46

Liver

T3N0M1

IV

Bone

0.025

2.78

Lung

0.004

3.56

Liver)

2.580

9.03

4

F

61

Kidney

T4N0M1

IV

Bone

0.068

0.76

Lung

0.001

3.22

7

F

58

Colon

T4N1M1

IV

Liver

0.017

10.12

8

F

46

Sarcoma

T2N0M1

IV

Lung

0.064

11.35

Liver

0.018

7.36

9

M

66

Colon

T3N2M1

IV

Lung

0.083

3.71

10

M

63

Colon

T3N2M1

IV

Lung

0.012

2.10

11

M

64

Esophagus

T3N0M1

IV

Lung

0.061

3.99

12

M

80

Colon

T3N2M1

IV

Abdomen

0.029

1.37

Bladder

0.040

1.10

(Liver)

0.048

13.57

13

F

55

Colon

T4N1M1

IIIB

Lung

0.002

4.94

14

M

62

NPC

T2N1M1

IV

Lung

0.052

7.87

  1. aHighest tumor uptake determined from ROI on 24-h SPECT imaging
  2. bPercentage injected activity per kilogram calculated from estimated tumor volume